193 related articles for article (PubMed ID: 34586829)
1. A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse models.
Yu X; Li D; Kottur J; Shen Y; Kim HS; Park KS; Tsai YH; Gong W; Wang J; Suzuki K; Parker J; Herring L; Kaniskan HÜ; Cai L; Jain R; Liu J; Aggarwal AK; Wang GG; Jin J
Sci Transl Med; 2021 Sep; 13(613):eabj1578. PubMed ID: 34586829
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia.
Grebien F; Vedadi M; Getlik M; Giambruno R; Grover A; Avellino R; Skucha A; Vittori S; Kuznetsova E; Smil D; Barsyte-Lovejoy D; Li F; Poda G; Schapira M; Wu H; Dong A; Senisterra G; Stukalov A; Huber KVM; Schönegger A; Marcellus R; Bilban M; Bock C; Brown PJ; Zuber J; Bennett KL; Al-Awar R; Delwel R; Nerlov C; Arrowsmith CH; Superti-Furga G
Nat Chem Biol; 2015 Aug; 11(8):571-578. PubMed ID: 26167872
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Potent and Selective WDR5 Proteolysis Targeting Chimeras as Potential Therapeutics for Pancreatic Cancer.
Yu X; Li D; Kottur J; Kim HS; Herring LE; Yu Y; Xie L; Hu X; Chen X; Cai L; Liu J; Aggarwal AK; Wang GG; Jin J
J Med Chem; 2023 Dec; 66(23):16168-16186. PubMed ID: 38019706
[TBL] [Abstract][Full Text] [Related]
4. Ribosome subunit attrition and activation of the p53-MDM4 axis dominate the response of MLL-rearranged cancer cells to WDR5 WIN site inhibition.
Howard GC; Wang J; Rose KL; Jones C; Patel P; Tsui T; Florian AC; Vlach L; Lorey SL; Grieb BC; Smith BN; Slota MJ; Reynolds EM; Goswami S; Savona MR; Mason FM; Lee T; Fesik S; Liu Q; Tansey WP
Elife; 2024 Apr; 12():. PubMed ID: 38682900
[TBL] [Abstract][Full Text] [Related]
5. Discovery and Structure-Based Optimization of Potent and Selective WD Repeat Domain 5 (WDR5) Inhibitors Containing a Dihydroisoquinolinone Bicyclic Core.
Tian J; Teuscher KB; Aho ER; Alvarado JR; Mills JJ; Meyers KM; Gogliotti RD; Han C; Macdonald JD; Sai J; Shaw JG; Sensintaffar JL; Zhao B; Rietz TA; Thomas LR; Payne WG; Moore WJ; Stott GM; Kondo J; Inoue M; Coffey RJ; Tansey WP; Stauffer SR; Lee T; Fesik SW
J Med Chem; 2020 Jan; 63(2):656-675. PubMed ID: 31858797
[TBL] [Abstract][Full Text] [Related]
6. Targeting WDR5: A WINning Anti-Cancer Strategy?
Aho ER; Weissmiller AM; Fesik SW; Tansey WP
Epigenet Insights; 2019; 12():2516865719865282. PubMed ID: 31360909
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a novel, highly potent EZH2 PROTAC degrader for targeting non-canonical oncogenic functions of EZH2.
Velez J; Dale B; Park KS; Kaniskan HÜ; Yu X; Jin J
Eur J Med Chem; 2024 Mar; 267():116154. PubMed ID: 38295690
[TBL] [Abstract][Full Text] [Related]
8. Human WDR5 promotes breast cancer growth and metastasis via KMT2-independent translation regulation.
Cai WL; Chen JF; Chen H; Wingrove E; Kurley SJ; Chan LH; Zhang M; Arnal-Estape A; Zhao M; Balabaki A; Li W; Yu X; Krop ED; Dou Y; Liu Y; Jin J; Westbrook TF; Nguyen DX; Yan Q
Elife; 2022 Aug; 11():. PubMed ID: 36043466
[TBL] [Abstract][Full Text] [Related]
9. The NTE domain of PTENα/β promotes cancer progression by interacting with WDR5 via its SSSRRSS motif.
Huang X; Zhang C; Shang X; Chen Y; Xiao Q; Wei Z; Wang G; Zhen X; Xu G; Min J; Shen S; Liu Y
Cell Death Dis; 2024 May; 15(5):335. PubMed ID: 38744853
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Potent 2-Aryl-6,7-dihydro-5 H-pyrrolo[1,2- a]imidazoles as WDR5-WIN-Site Inhibitors Using Fragment-Based Methods and Structure-Based Design.
Wang F; Jeon KO; Salovich JM; Macdonald JD; Alvarado J; Gogliotti RD; Phan J; Olejniczak ET; Sun Q; Wang S; Camper D; Yuh JP; Shaw JG; Sai J; Rossanese OW; Tansey WP; Stauffer SR; Fesik SW
J Med Chem; 2018 Jul; 61(13):5623-5642. PubMed ID: 29889518
[TBL] [Abstract][Full Text] [Related]
11. WIN site inhibition disrupts a subset of WDR5 function.
Siladi AJ; Wang J; Florian AC; Thomas LR; Creighton JH; Matlock BK; Flaherty DK; Lorey SL; Howard GC; Fesik SW; Weissmiller AM; Liu Q; Tansey WP
Sci Rep; 2022 Feb; 12(1):1848. PubMed ID: 35115608
[TBL] [Abstract][Full Text] [Related]
12. Unannotated microprotein EMBOW regulates the interactome and chromatin and mitotic functions of WDR5.
Chen Y; Su H; Zhao J; Na Z; Jiang K; Bacchiocchi A; Loh KH; Halaban R; Wang Z; Cao X; Slavoff SA
Cell Rep; 2023 Sep; 42(9):113145. PubMed ID: 37725512
[TBL] [Abstract][Full Text] [Related]
13. Overlapping characteristics of weak interactions of two transcriptional regulators with WDR5.
Ahmad M; Imran A; Movileanu L
Int J Biol Macromol; 2024 Feb; 258(Pt 2):128969. PubMed ID: 38158065
[TBL] [Abstract][Full Text] [Related]
14. Discovery of Potent Orally Bioavailable WD Repeat Domain 5 (WDR5) Inhibitors Using a Pharmacophore-Based Optimization.
Teuscher KB; Meyers KM; Wei Q; Mills JJ; Tian J; Alvarado J; Sai J; Van Meveren M; South TM; Rietz TA; Zhao B; Moore WJ; Stott GM; Tansey WP; Lee T; Fesik SW
J Med Chem; 2022 Apr; 65(8):6287-6312. PubMed ID: 35436124
[TBL] [Abstract][Full Text] [Related]
15. Displacement of WDR5 from Chromatin by a WIN Site Inhibitor with Picomolar Affinity.
Aho ER; Wang J; Gogliotti RD; Howard GC; Phan J; Acharya P; Macdonald JD; Cheng K; Lorey SL; Lu B; Wenzel S; Foshage AM; Alvarado J; Wang F; Shaw JG; Zhao B; Weissmiller AM; Thomas LR; Vakoc CR; Hall MD; Hiebert SW; Liu Q; Stauffer SR; Fesik SW; Tansey WP
Cell Rep; 2019 Mar; 26(11):2916-2928.e13. PubMed ID: 30865883
[TBL] [Abstract][Full Text] [Related]
16. Dual IKZF2 and CK1α degrader targets acute myeloid leukemia cells.
Park SM; Miyamoto DK; Han GYQ; Chan M; Curnutt NM; Tran NL; Velleca A; Kim JH; Schurer A; Chang K; Xu W; Kharas MG; Woo CM
Cancer Cell; 2023 Apr; 41(4):726-739.e11. PubMed ID: 36898380
[TBL] [Abstract][Full Text] [Related]
17. WDR5 is a conserved regulator of protein synthesis gene expression.
Bryan AF; Wang J; Howard GC; Guarnaccia AD; Woodley CM; Aho ER; Rellinger EJ; Matlock BK; Flaherty DK; Lorey SL; Chung DH; Fesik SW; Liu Q; Weissmiller AM; Tansey WP
Nucleic Acids Res; 2020 Apr; 48(6):2924-2941. PubMed ID: 31996893
[TBL] [Abstract][Full Text] [Related]
18. Impact of WIN site inhibitor on the WDR5 interactome.
Guarnaccia AD; Rose KL; Wang J; Zhao B; Popay TM; Wang CE; Guerrazzi K; Hill S; Woodley CM; Hansen TJ; Lorey SL; Shaw JG; Payne WG; Weissmiller AM; Olejniczak ET; Fesik SW; Liu Q; Tansey WP
Cell Rep; 2021 Jan; 34(3):108636. PubMed ID: 33472061
[TBL] [Abstract][Full Text] [Related]
19. Structural studies of WDR5 in complex with MBD3C WIN motif reveal a unique binding mode.
Yang Y; Xu L; Zhang S; Yao L; Ding Y; Li W; Chen X
J Biol Chem; 2024 Jun; ():107468. PubMed ID: 38876301
[TBL] [Abstract][Full Text] [Related]
20. WD Repeat Domain 5 Inhibitors for Cancer Therapy: Not What You Think.
Weissmiller AM; Fesik SW; Tansey WP
J Clin Med; 2024 Jan; 13(1):. PubMed ID: 38202281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
